Thu, Aug 21, 2014, 12:28 PM EDT - U.S. Markets close in 3 hrs 32 mins

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • weightbayou weightbayou May 14, 2013 3:34 PM Flag

    Immunomodulatory Therapeutic Antibodies for Cancer Conference - Day 2

    Immunomodulatory Therapeutic Antibodies for Cancer Conference - Day 2
    THURSDAY, AUGUST 15, 2013
    Emerging Targets
    8:25 am Chairperson's Opening Remarks
    Lawrence J. Thomas, Ph.D., DABT, CMAR, Senior Director, Preclinical Research and Development, Celldex Therapeutics, Inc.
    8:30 Immunocytokines: A Novel Potent Class of Armed Antibodies
    Catherine Hutchinson, Ph.D., Research Scientist, Philochem, Switzerland
    The severe toxicity of recombinant cytokines even at low doses limits their therapeutic potential, but this can be mitigated by using monoclonal antibodies to target their delivery. This talk will cover the latest advanced preclinical and clinical data of the Philogen group, detailing the discovery and development of armed antibodies against angiogenesis-specific markers, which are attractive targets relevant to many angioproliferative diseases.
    9:00 Mechanism of Action and Progress Update for MGA271: An Fc-Enhanced mAb Targeting B7-H3 in Solid Tumors
    Paul Moore, Ph.D., Vice President, Cell Biology & Immunology, Macrogenics
    Characterization of murine monoclonal antibodies generated from cancer cell and/or stem cell-based immunizations identified a panel targeting the immunoregulatory protein B7-H3 displaying broad tumor reactivity but limited binding to normal tissue. Preclinical evaluation of MGA271, an Fc-enhanced anti-B7H3 mAb, revealed strong ADCC activity against a broad range of tumor cell types, potent antitumor activity in xenograft models employing human FcR transgenic mice and a favorable safety profile in non-human primate toxicology studies. A phase I/IIa clinical study of MGA271 in patients with B7-H3-positive metastatic or recurrent adenocarcinoma is currently recruiting patients.
    9:30 Preclinical Update: Development of a Human Anti-CD27 Monoclonal Antibody as a Potential Cancer Therapy
    Lawrence J. Thomas, Ph.D., DABT, CMAR, Senior Director, Preclinical Research and Development, Celldex Therapeutics.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CLDX
14.38-0.73(-4.83%)12:28 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.